Compare Amphastar Pharmaceuticals Inc (AMPH) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Thomson Reuters Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Thomson Reuters Corp trades at $94.22 (market cap $38.95B). The key difference: Thomson Reuters Corp is far larger — about 47.2× Amphastar Pharmaceuticals Inc's market cap, and Thomson Reuters Corp pays a 2.92% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TRI | |
|---|---|---|
Market Cap | $826.08M | $38.95B |
Sector | Health | Industrials |
52-Week High | $30.81 | $214.21 |
52-Week Low | $16.87 | $76.55 |
Enterprise Value | $1.22B | $40.91B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Thomson Reuters (TRI) trades at $89.65, up 0.92% today, with a bullish technical signal and strong support at $88. The company shows robust fundamentals with a 19.93% net income margin and consistent earnings beats, though Q4 2025 missed expectations. Recent AI partnerships and a special dividend highlight strategic moves, while cash flow turned negative in 2025 due to investing activities.
Outlook is positive with a consensus price target of $129.96, implying 45% upside, supported by 51.85% analyst buy ratings. Risks include AI implementation challenges and revenue volatility, but the stock's valuation at P/E 25.8 appears reasonable given growth prospects in legal and compliance sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
